20230724-招银国际-科笛-B-02487.HK-Well-positioned_to_capture_broader_dermatology_market_potential_54页

CMB International Global Markets has initiated coverage for Cutia Therapeutics (stock code 2487 HK) with a BUY recommendation and a target price of HK$33.21, which represents a 70.3% upside from the current price of HK$19.50. The coverage is based on the company's extensive and differentiated product pipeline targeting the rapidly growing Chinese dermatology market.

Key Investment Thesis:

• Cutia possesses a fully integrated CATAME technology platform, enabling the development of diverse dermatology products. These include 11 products across therapeutic areas like localized adipose accumulation management, scalp diseases, and topical anesthesia.
• The company's pipeline has strong potential in the broader dermatology market, expected to reach RMB1,039 billion by 2030 in China, driven by rising consumer awareness and unmet medical needs.
• Financial projections estimate total revenue of RMB37 million for 2023E, RMB108 million for 2024E, and RMB328 million for 2025E, with a voluntary net loss of RMB282 million in 2023E.

Valuation and Pricing:

• The target price of HK$33.21 is derived from a 13-year discounted cash flow (DCF) model using a weighted average cost of capital (WACC) of 13.1% and a terminal growth rate of 2.0%. Sensitivity analysis shows the valuation is sensitive to WACC and growth assumptions.

Investment Risks:

• Primarily related to the development and regulatory approval of product candidates, reliance on collaborations, and manufacturing challenges. Delays in clinical trials or commercialization could impact the business.

This summary captures the core elements of the report, including recommendations, market outlook, financials, risks, and valuation.